Table 1.
Disease- and treatment-related data (n = 14).
| Number of Patients (%) or Mean (SD) | |
|---|---|
| Age at diagnosis (years) | 9.6 (5) |
| Weight (kg) * | 43.8 (22.3) |
| Weight percentile * | 71.8 (33.9) |
| Weight Z-score * | 0.9 (1.2) |
| Height (m) * | 1.4 (0.3) |
| Height percentile * | 52.8 (33.3) |
| Height Z-score * | 0.1 (1.2) |
| BMI (kg/cm2) * | 21.1 (4.8) |
| BMI percentile * | 87.9 (17.3) |
| BMI Z-score * | 0.8 (1.6) |
| Histology | |
| Germ cell tumor | 8 (57%) |
| Medulloblastoma | 4 (29%) |
| Ependymoma | 2 (14%) |
| Primary localization | |
| Anterior cranial fossa | 0 (0%) |
| Middle cranial fossa | 8 (57%) |
| Posterior cranial fossa | 6 (43%) |
| Presence of metastasis at diagnosis | 1 (7%) |
| Patients subjected to cranial radiotherapy | 14 (100%) |
| Patients subjected to spinal radiotherapy | 5 (36%) |
| Cranial radiotherapy dose (Gy) | 56.7 (16.6) |
| Spinal radiotherapy dose (Gy) | 30 (0) |
| Patients subjected to chemotherapy | 12 (86%) |
| Patients subjected to steroid therapy (more than 14 days) | 10 (71%) |
| Patients subjected to ASCT | 2 (14%) |
| Relapsed disease | 2 (14%) |
| Endocrinological deficiencies | 9 (64%) |
| Panhypopituitarism | 4 (29%) |
| Hypothyroidism | 2 (14%) |
| GH deficiency | 3 (21%) |
| Age at the enrollement (years) | 24.9 (3.9) |
| Time of follow up at the enrollement (months) | 171 (54) |
* at diagnosis. ASCT: autologous stem cell transplant; BMI: body mass index; GH: growth factor.